The market taxonomy by type separates Acute Ischemic Stroke Diagnosis into three principal modalities: Imaging‑based, Biomarker‑based, and Clinical‑scoring systems. Imaging‑based methods dominate with an estimated 70 % share, encompassing non‑contrast CT, diffusion‑weighted MRI, CT angiography (CTA), and MR angiography (MRA). CT remains the workhorse due to speed and availability, while MRI offers superior tissue characterization, driving higher equipment costs but also premium service contracts. Biomarker‑based diagnostics, currently accounting for roughly 15 % of market value, include plasma assays for neurofilament light chain, D‑dimer, and emerging proteomic panels that aim to shorten diagnostic latency when imaging is inaccessible. Clinical‑scoring systems such as NIHSS, FAST, and Cincinnati Prehospital Stroke Scale constitute the remaining 15 % and generate revenue through software licensing, decision‑support algorithms, and training services. Each type contributes distinct cost structures: imaging drives capital‑intensive hardware and consumable spend, biomarkers rely on reagent turnover, and scoring tools depend on subscription‑based analytics, together defining the overall market size.